Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
STAMPEDE: Abiraterone acetate plus prednisolone or docetaxel

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.09.17
Views: 1111

Matthew Sydes - Medical Research Council, London, UK

Matthew Sydes talks with ecancer at the ESMO 2017 Congress about the STAMPEDE trial, assessing the use of abiraterone acetate plus prednisolone or abiraterone acetate plus docetaxel for patients with high-risk prostate cancer starting long-term androgen deprivation therapy.

He goes on to discuss the advantages of both treatments and outlines when it might be best to use either therapy. 

Read more about these results here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence